Immunotherapy Coverage from Every Angle
Advertisement
Advertisement

Recent News

Daratumumab-Based Combination Therapy for Newly Diagnosed Multiple Myeloma
ASCO-SITC 2020: Genetics Research Hints at Regulator of T-Cell Responses in Colorectal Cancer
GU Cancers Symposium 2020: Long-Term Data Support Nivolumab vs Everolimus in Kidney Cancer
ASCO–SITC 2020: Interim Trial Results With Pepinemab/Avelumab in Advanced NSCLC
Can Influenza Vaccines Trigger Immune Response in Patients With Melanoma?
GI Cancers Symposium 2020: Pertuzumab Plus Trastuzumab in HER2-Positive Colorectal Cancer
ASCO-SITC 2020: Radiation Recall Pneumonitis and Nivolumab for Lung Cancer
Phase I Trial Results With Immunotherapy bb21217 for Resistant Multiple Myeloma
ASCO-SITC 2020: Is Immune Primer in Renal Cell Cancer Ready for Prime Time?
Dynamics of DNA Methylation in CLL Patients Treated With Chemoimmunotherapy
NCI-MATCH Study: Next Phase for Nivolumab Beyond Colorectal Cancer
Matching Tumor Mutations to Treatment for Salivary Gland Cancer
GI Cancers Symposium 2020: TAPUR Study Findings for Pembrolizumab in Colorectal Cancer
B and T Immune Cells: A Biomarker of Response to Immunotherapy for Breast Cancer?
GI Cancers Symposium 2020: Quality-of-Life Results From the BEACON CRC Trial
Combination Therapy for Frail and Unfit Patients Newly Diagnosed With Multiple Myeloma
Can B Cells Determine Immunotherapy Responses in Advanced Melanoma?
T-DM1 as Monotherapy for Early HER2-Positive Breast Cancer
GI Cancers Symposium 2020: Pembrolizumab in Advanced Anal Cancer
Dual-Target CAR T-Cell Therapy in Resistant Multiple Myeloma
NCI-MATCH Trial Subprotocol: T-DM1 in HER2-Positive Salivary Gland Tumors
Priority Review Granted by FDA to Immunotherapy Combination in Lung Cancer
FDA Grants Priority Review to Olaparib/Bevacizumab as Maintenance Therapy for Ovarian Cancer
Early-Phase Results With CD19-Directed Immunotherapy for CLL
Novel Monoclonal Antibody in Relapsed or Refractory Multiple Myeloma
Early Results With Chemotherapy-Free Triplet Regimen in Resistant CLL
Pertuzumab Plus Standard Treatment in HER2-Positive Early Breast Cancer
KEYNOTE-522 in Triple-Negative Breast Cancer: Pathologic Complete Response Rates With Pembrolizumab
‘Priming’ Patients With Advanced Melanoma for Retreatment With Checkpoint Inhibitors
Two-Year Survival Results With Neoadjuvant T-VEC in Resectable Melanoma
ASH 2019: Dose-Finding Study of Novel Immunotherapy for Resistant Myeloma
SMR 2019: T-VEC Plus Ipilimumab in Advanced Melanoma
KEYNOTE-048 Opens Door Farther for Pembrolizumab in Head/Neck Cancer
Can Skin Reactions Portend Clinical Benefit in Patients With NSCLC?
ASH 2019: Early Trial Results With CAR T-Cell Therapy for Resistant Myeloma
Copyright © 2020 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.